Recepton is a newly founded biotech company focused on cancer immunotherapy, the process of mobilizing the immune system to kill cancer.
In particular, we have designed:
- a novel service platform composed of a broad portfolio of the recombinant immune checkpoint receptors. The platform can be used for rapid typing and testing of new types of inhibitors for the immunoreceptors, especially for the signaling axis of the programmed cell death protein 1 (PD-1) and its ligand, protein PD-L1.
- chemistry synthetic and biophysical methods of rational drug design, cell-based assays, preclinical studies that aim at developing new types of small-molecule inhibitors for the immune checkpoint blockade (ICB).